Just Published: "Bulgaria Pharmaceuticals & Healthcare Report Q2 2015"
Recently published research from Business Monitor International, "Bulgaria Pharmaceuticals & Healthcare Report Q2 2015", is now available at Fast Market Research
[USPRwire, Tue Feb 17 2015] In 2015, we expect the fallout from the banking and NHIF funding crises to impact pharmaceutical and healthcare spending, but given the passage of reforms to healthcare financing, we hold a more positive view for the long term development of the pharmaceutical & healthcare sector.
Headline Expenditure Projections
* Pharmaceuticals: BGN2.50bn (USD1.71bn) in 2014 to BGN2.41bn (USD1.54bn) in 2015; -3.7% in local currency terms and -10.2% in US dollar terms. Forecast revised downwards from Q 1 15.
* Healthcare: BGN6.06bn (USD4.14bn) in 2014 to BGN5.81bn (USD3.70bn) in 2015; -4.1% in local currency terms and -10.6% in US dollar terms. Forecast revised significantly downwards from Q115.
Risk/Reward Ratings: In Q2 2015, Bulgaria's Risk Reward Index score (52.6) is just above above the regional average (51.1), placing it in eighth place out of 20 countries in the CEE table. The scores take into account the challenges for drugmakers operating in Bulgaria, such as the downward pressure on the prices of drugs and the uncertain political outlook, in addition to positive factors such as the increasing per capita consumption of medicines from a relatively low base and the country's ageing population.
* In January 2015, the Bulgarian passed legislation amending the Health Insurance Act that shored up the national health insurer's funding over the long term, established a basic package of benefits for insured Bulgarians, increases the state's contributions to healthcare insurance from 2016 and mandates that the National health Insurance Fund (NHIF) negotiate discounts for pharmaceuticals that are to be added to the Positive Reimbursement List.
* At the beginning of 2015, the National Council on the Prices and Reimbursement of Medicinal Products stated it would fine pharmaceutical companies which failed to notify the Bulgarian authorities that they had reduced their prices in any of the 10 reference countries. The law obliges...
The Bulgaria Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Bulgaria Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bulgaria pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Bulgaria, to test other views - a key input for successful budgeting and strategic business planning in the Bulgarian pharmaceutical and healthcare market.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
You may also be interested in these related reports:
